To include your compound in the COVID-19 Resource Center, submit it here.

Izun reports Phase II data for IZN-6N4 in oral mucositis

In October, Izun Pharmaceuticals Corp. (New York, N.Y.) reported data from a Phase

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE